A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy.

Trial Profile

A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs SB 728 T (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Sponsors Sangamo BioSciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 May 2015 Results presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy, according to a Sangamo Biosciences media release.
    • 14 May 2015 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top